Cargando…

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia

PURPOSE: To assess changes in lower urinary tract symptoms (LUTS), prostate volume, and serum prostate-specific antigen (PSA) after discontinuation of 5-alpha reductase inhibitor (5ARI) combination therapy in patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: From December 2003...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Won, Jung, Jae Hung, Kang, Tae Wook, Song, Jae Mann, Chung, Hyun Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897631/ https://www.ncbi.nlm.nih.gov/pubmed/24466398 http://dx.doi.org/10.4111/kju.2014.55.1.52

Ejemplares similares

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2018)

Corrigendum: Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2019)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study
por: Kim, Young Won, et al.
Publicado: (2015)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
por: Ayodele, Olulade, et al.
Publicado: (2021)

Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia
por: Kim, Su Kang, et al.
Publicado: (2014)

Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014)

Aconiti Lateralis Radix Preparata, the Dried Root of Aconitum carmichaelii Debx., Improves Benign Prostatic Hyperplasia via Suppressing 5-Alpha Reductase and Inducing Prostate Cell Apoptosis
por: Park, Jinbong, et al.
Publicado: (2019)

Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase
por: Youn, Dong-Hyun, et al.
Publicado: (2016)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

The association of benign prostatic hyperplasia with lower urinary tract stones in adult men: A retrospective multicenter study
por: Jung, Jae Hung, et al.
Publicado: (2018)

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy
por: Kang, Tae Wook, et al.
Publicado: (2020)

Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review
por: Kang, Tae Wook, et al.
Publicado: (2021)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

Letter to the editor: Korean clinical practice guideline for benign prostatic hyperplasia
por: Jung, Jae Hung, et al.
Publicado: (2016)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Inflammatory response to Trichomonas vaginalis in the pathogenesis of prostatitis and benign prostatic hyperplasia
por: Han, Ik-Hwan, et al.
Publicado: (2023)

Korean clinical practice guideline for benign prostatic hyperplasia
por: Yeo, Jeong Kyun, et al.
Publicado: (2016)

Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures
por: Franco, Juan V.A., et al.
Publicado: (2023)

Relationship between Intravesical Prostatic Protrusion and Postoperative Outcomes in Patients with Benign Prostatic Hyperplasia
por: Lee, Jong Woo, et al.
Publicado: (2012)

Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment
por: Sung, Hyun Hwan, et al.
Publicado: (2019)

Expression and Localization of Aquaporins in Benign Prostate Hyperplasia and Prostate Cancer
por: Hwang, Insang, et al.
Publicado: (2012)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
por: Chung, Jae-Wook, et al.
Publicado: (2011)

Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis
por: Kim, Hyun Jung, et al.
Publicado: (2017)

Current Laser Treatments for Benign Prostatic Hyperplasia
por: Son, Hwancheol, et al.
Publicado: (2010)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Use of 5-Alpha-Reductase Inhibitors Did Not Increase the Risk of Cardiovascular Diseases in Patients with Benign Prostate Hyperplasia: A Five-Year Follow-Up Study
por: Hsieh, Teng-Fu, et al.
Publicado: (2015)

Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men
por: Chang, Jooyoung, et al.
Publicado: (2019)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Inhibits Benign Prostatic Hyperplasia In Vitro and In Vivo
por: Song, Jun-Hui, et al.
Publicado: (2020)

Changes in Nocturia after Photoselective Vaporization of the Prostate for Patients with Benign Prostatic Hyperplasia
por: Lee, Chang Ju, et al.
Publicado: (2010)

In vivo evaluation of hot water extract of Acorus gramineus root against benign prostatic hyperplasia
por: Moon, Joo-Myung, et al.
Publicado: (2017)

Benign Prostatic Hyperplasia
Publicado: (2015)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ap98guud0lc0gj2sjq830jc9ja